Pfizer Advances Duchenne Drug As It Prioritizes Gene Therapy
High value deal with Bamboo Therapeutics starts to come to fruition with start of small study in Duchenne muscular dystrophy, which aims at underlying cause as opposed to symptoms of disease.
You may also be interested in...
Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.
With its first AAV gene therapy candidate from Bamboo Therapeutics expected to report data in 2019, Pfizer’s efforts to get in the DMD competition now center on that modality.
US FDA Commissioner teases endpoints, suggests accelerated approval plan and post-marketing considerations for gene therapies targeting hemophilia.